|
| 书名 |
血液和肿瘤专业实用药物学 | | 并列正书名 |
Practical pharmacology for Hematological and Oncology | | 丛书多卷书否 |
N | | ISBN |
978-7-5390-6633-2 | | 主要责任者 |
余健民,[美]乐泉 | | 责任方式 |
主编 | | 出版者 |
江西科学技术出版社 | | 出版地 |
南昌 | | 出版日期 |
2019-03 | | 页码 |
1-1117 | | 字数 |
1700 | | 开本 |
16 | | 定价 |
200.00 | | 作品语种 |
中 | | 整书中图分类号 |
R733.053 | | 参考文献 |
1.陈新谦,金有豫,汤光.新编药物学.第17版.北京:人民卫生出版社,2011
2.芮耀诚.现代药物学.第1版.北京:人民军医出版社,1999
3.杨世杰.药理学.北京:人民卫生出版社,2005
4.国家食品药品监督管理局药品审评中心、四川美康医药软件研究开发有限公司合编.药物临床信息参考.成都.四川出版集团,四川科学技术出版社.2005
5.陈灏珠、林果为、王吉耀主编.实用内科学.第15版.北京:人民卫生出版社.2017
6.余健民、胡建新主编.呼吸危重症监护及药物治疗学.南昌:江西出版集团、江西科学技术出版社.2007
7.国家药典委员会.中华人民共和国药典临床用药须知:化学药和生物制品卷.2010年版.北京:中国医药科技出版社,2011
8.余健民主编.呼吸内科临床手册.南昌:江西科技出版社.1999
9.傅宏义.新编医院药物大全.第1版.北京:中国医药科技出版社,1999
10.中华医学会编辑出版部:法定计量单位在医学上的应用.第2版.北京:人民军医出版社.1991
11.张文康,潘学田.中国进口药品实用手册1996～1997.第1版.北京:北京科学技术出版社.1996
12.国家药品监督管理局安全监管司,国家药品监督管理局药品评价中心.国家基本药物(西药).第2版.北京:人民卫生出版社,2002
13.MCDEX合理用药信息支持系统.成都:四川美康医药软件研究开发有限公司.2014/
14.罗明生,高天惠,劳家华.现代临床药物大典.第1版.成都:四川科学技术出版社,2001.360
15.孙琛.临床用药大全.第1版.上海:中国大百科全书出版社上海分社,1995.111
16.Hemmelgarn BR, Moist LM, Lok CE, et al: Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364(4):303～312.
17.Product Information: RETAVASE(R) IV injection, reteplase, recombinant IV injection. PDL BioPharma,Inc, Fremont, CA, 2006.
18.Vanderschueren S, Barrios L, Kerdsinchai P, et al: A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92:2044～2049.
19.Shiraishi T, Kubo T, Okumura SI, et al: Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy. Acta Otolaryngol (Stockh) 1993; Suppl 501:46～50.
20.Monagle P, Chan A, Massicotte P, et al: Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):645～687.
21.Collen D & Van de Werf F: Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87:1850～1853.
22.Dereure O, Bessis D, Labavre T, et al: Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte colony-stimulating factor treatment. Br J Dermatol 2000; 142:834～836.
23.Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24(19):3187～3205.
24.Ippoliti C, Przepiorka D, Smith T, et al: Adverse effects of molgramostim in marrow transplant recipients. Clin Pharm 1993; 12:520～525.
25.Lautenschlager S, Itin PH, Hirsbrunner P, et al: Subcorneal pustular dermatosis at the injection site of recombinant human granulocyte-macrophage colony-stimulating factor in a patient with IgA myeloma. J Am Acad Dermatol 1994; 30:787～789.
26.Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357(22):2237～2247.
27.Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371(9610):395～403.
28.Product Information: NEUMEGA(R) subcutaneous lyophilized powder injection, oprelvekin subcutaneous lyophilized powder injection. Wyeth Pharmaceuticals Inc. (per FDA), Philadelphia, PA, 2009.
29.Ichida F, Uese K, Tsubata S, et al: Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997; 80:662～664.
30.Product Information: dipyridamole oral tablets, dipyridamole oral tablets. Zydus Pharmaceuticals USA, Inc, Princeton, NJ, 2008.
31.Gotoh F, Tohgi H, Hirai S, et al: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9(4):147～157.
32.Kobayashi K, Maeda K, Koshikawa S, et al: Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis. A multicenter collaborative double blind study. Thrombosis Res 1980; 20:255～261.
33.Kereiakes DJ, Kleiman NS, Ambrose J, et al: Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27:536～542.
34.Schering Corporation: Dear Healthcare Professional Letter for INTEGRILIN(R) [eptifibatide]. Schering Corporation. Kenilworth, NJ. 2007. Available from URL: file://\\\\Tsh\\den\\ Departments\\Editorial\\ Package_Inserts\\ eptifibatide_injection_2007 _(Schering)_CMS2414538.pdf.
35.Kieffer E, Bahnini A, Mouren X, et al: A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication; findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001; 20:58～65.
36.Fattouch K, Sbraga F, Sampognaro R, et al: Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7(2):119～123.
37.Product Information: Stimate(R) nasal spray, desmopressin acetate nasal spray. CSL Behring LLC (per FDA), King of Prussia, PA, 2011.
38.Product Information: HEMOFIL(R) M IV injection, antihemophilic factor (human) method m, monoclonal purified IV injection. Baxter Healthcare Corporation (per manufacturer), Westlake Village, CA, 2010.
39.US Food and Drug Administration: Manufacturer Removes Remaining Stocks of Trasylol. US Food and Drug Administration. Rockville, MD. 2008. Available from URL:.
40.Mustapha A, Yakasai IA, & Aguye IA: Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. Europ J Drug Metab Pharmacokinet 1996; 21(3):224～226.
41.Ockelford PA, Patterson J, & Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62:1046～1049.
42.Szolar-Platzer C, Aberer W, & Kranke B: Delayed-type skin reaction to the heparin-alternative danaparoid. J Am Acad Dermatol 2000; 43:920～922.
43.Falck-Ytter Y, Francis CW, Johanson NA, et al: Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e278S～e325S.
44.Dorffler-Melly J, de Jonge E, de Pont AC, et al: Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359:849～850.
45.Laji K, Rhidha B, John R, et al: Abnormal serum free thyroid hormone levels due to heparin administration. Q J Med 2001; 94:471～473.
46.Monagle P, Chalmers E, Chan A, et al: Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):887S～968S.
47.AMA Department of DrugsAMA Department of Drugs: Drug Evaluations Subscription, American Medical Association, Chicago, 1991.
48.Keegan SP, Gallagher EM, Ernst NE, et al: Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009; 43(1):19～27.
49.Lambert JP & Cormier J: Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001; 21(4):509～512.
50.Oliviero U, Sorrentino GP, De Paola P, et al: Effects of the treatment with matrix on elderly people with chronic articular degeneration. Drugs Exp Clin Res 1991; 17(1):45～51.
51.Kruth P, Brosi E, Fux R, et al: Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother 2004; 38:257～260.
52.Warkentin TE, Greinacher A, Koster A, et al: Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S～380S.
53.Bourgeois P, Chales G, Dehais J, et al: Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3x400 mg/day vs placebo. Osteoarthritis Cartilage 1998; 6(suppl A):25～30.
54.Hu ZJ, Iwama H, Suzuki R, et al: Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med 1999a; 25:524～527.
55.Product Information: Cymbalta(R) oral delayed-release capsules, duloxetine HCl oral delayed-release capsules. Eli Lilly and Company, Indianapolis, IN,2011.
56.Schneider M, Valentine S, Clarke GM, et al: Acute renal failure in cardiac surgical patients, potentiated by gentamicin and calcium. Anaesth Intensive Care 1996; 24:647～650.
57.Product Information: MATULANE(R) oral capsule, procarbazine hydrochloride oral capsule. Sigma-tau Pharmaceuticals, Inc, Gaithersburg, MD, 2004.
58.Product Information: EMCYT oral capsule, estramustine phosphate sodium oral capsule. Pharmacia and Upjohn Company, New York, NY, 2008.
59.Moertel CG, Johnson CM, McKusick MA, et al: The management of patients with advanced carcinoid tumors and islet cell carcinomas.. Ann Intern Med 1994; 120:302～9.
60.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3
61.Tubergen DG, Krailo MD, Meadows A, et al: Comparison of treatment regimens for pediatric lymphoblastic non-hodgkin＇s lymphoma: a childrens cancer group study. J Clin Oncol 1995; 13(6):1368～1376.
62.Product Information: EMCYT oral capsule, estramustine phosphate sodium oral capsule. Pharmacia and Upjohn Company, New York, NY, 2008.
63.Canadian Pharmacists Association: Compendium of Pharmaceuticals and Specialties, Publisher. Canadian Pharmacists Association, Toronto, ON, 2003
64.Product Information: ALKERAN(R) oral tablets, melphalan oral tablets. GlaxoSmithKline, Research Triangle Park, NC, 2008.
65.Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11(7):1276～1285.
66.Jung EJ , Ryu CG , Kim G , et al: Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res 2012; 32(8):3357～3362
67.Welink J, Vermorken JB, Boven E, et al: Pharmacokinetics of lobaplatin in patients with advanced solid tumors, including patients with impaired renal or liver function (abstract 1502). Proc Am Assoc Cancer Res 1997a; 38:223.
68.Adachi S, Ogasawara T, Yamasaki N, et al: A pilot study of nedaplatin and etoposide for recurrent gynecological malignancies. Oncol Rep 1998; 5:881～894.
69.Product Information: carboplatin intravenous injection, carboplatin intravenous injection. Parenta Pharmaceuticals, West Columbia, SC, 2008.
70.Chamberlain MC, Khatibi S, Kim JC, et al: Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). Arch Neurol 1993; 50:261～264.
71.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3.
72.Momparler RL, Bouffard DY, Momparler LF, et al: Pilot phase I-II study on 5-aza-2＇-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs 1997; 8:358～368.
73.Product Information: fludarabine phosphate IV injection, fludarabine phosphate IV injection. Sandoz, Princeton, NJ, 2010.
74.Laszlo D, Andreola G, Rigacci L, et al: Rituximab and subcutaneous 2-chloro-2＇-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010; 28(13):2233～2238.
75.Judson I, Maughan T, Beale P, et al: Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br J Cancer 1998a; 78(9):1188～1193.
76.Product Information: fludarabine phosphate IV injection, fludarabine phosphate IV injection. Sandoz, Princeton, NJ, 2010.
77.Johnston DL, Bains T, Mandel K, et al: Fatal neurotoxicity in a patient with down syndrome treated with chemotherapy, irradiation, stem cell transplant, and clofarabine. J Pediatr Hematol Oncol 2010; 32(3):111～113.
78.Adjei AA, Erlichman C, Sloan JA, et al: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18(8):1748～1757.
79.Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109(2):405～411.
80.Product Information: FOLOTYN(TM) solution for IV injection, pralatrexate solution for IV injection. Allos Therapeutics, Inc., Westminister, CO, 2009
81.George J, Present DH, Pou R, et al: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996
82.Schaaf LJ, Dobbs BR, Edwards IR, et al: The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. Eur J Clin Pharmacol 1988a; 34:439～443.
83.Product Information: GEMZAR(R) IV injection, gemcitabine hydrochloride IV injection. Eli Lilly and Company, Indianapolis, IN, 2010.
84.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3
85.Miller LP, Pyesmany AF, Wolff LJ, et al: Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. Cancer 1991; 67:2235～2240.
86.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3.
87.Product Information: epirubicin hydrochloride IV injection, epirubicin hydrochloride IV injection. Teva Parenteral Medicines, Inc, Irvine, CA, 2010.
88.Loehrer PJ Sr, Kim K, Aisner SC, et al: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12(6):1164～1168.
89.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3.
90.Ikeda S, Ishihara K, & Matsunaka N: Peplomycin therapy for skin cancer in Japan. Drugs Exptl Clin Res 1986; 12:247～255.
91.Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32):5397～5403.
92.Ikeda S, Ishihara K, & Matsunaka N: Peplomycin therapy for skin cancer in Japan. Drugs Exptl Clin Res 1986; 12:247～255.
93.Centers for Disease Control and Prevention : General Recommendations on Immunization. MMWR 2011; 60(2):3.
94.Garnick MB, Ernst T, & Martinez F: Acute febrile reaction to streptozocin. N Engl J Med 1984; 311:798.
95.Oka S: A review of clinical studies of pepleomycin. Recent Results Cancer Res 1980; 74:163～171.
96.Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32):5397～5403.
97.FDALabel(2015-02-03)-IBRANCE(Palbociclib Capsules)(Pfizer Labs)
98.Hilbe W, Thaler J, Eisterer W, et al: Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leukemia Res 1994; 18:655～658.
99.Chevallier B, Mignot L, Delozier T, et al: Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol 1992; 15(5):395～398.
100.Product Information: epirubicin hydrochloride IV injection, epirubicin hydrochloride IV injection. Teva Parenteral Medicines, Inc, Irvine, CA, 2010.
101.Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22:2159～2166.
102.Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32):5397～5403.
103.FDALabel(2015-02-03)-IBRANCE(Palbociclib Capsules)(Pfizer Labs)
104.Ikeda S, Ishihara K, & Matsunaka N: Peplomycin therapy for skin cancer in Japan. Drugs Exptl Clin Res 1986; 12:247～255.
105.Hilbe W, Thaler J, Eisterer W, et al: Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leukemia Res 1994; 18:655～658.
106.Miller LP, Pyesmany AF, Wolff LJ, et al: Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. Cancer 1991; 67:2235～2240.
107.Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32):5397～5403.
108.Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32):5397～5403.
109.FDALabel(2014-08-01)-HALAVEN(Eribulin Mesylate Injection)(Eisai Inc.)
110.Andersson M , Lidbrink E , Bjerre K , et al: Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study. J Clin Oncol 2011; 29(3):264～271.
111.Gasparini M, Tondini C, Rottoli L, et al: Continuous cisplatin infusion in combination with vincristine and high-dose methotrexate for advanced osteogenic sarcoma. Am J Clin Oncol 1987; 10:152～155.
112.FDALabel(2014-03-13)-Docetaxel Injection(Pfizer, Inc.)
113.FDALabel(2015-06-18)-JEVTANA(Cabazitaxel Injection)(sanofi-aventis U.S. LLC)
114.Sparano JA, Vrdoljak E, Rixe O, et al: Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28(21):3256～3263.
115.Slovacek L & Slovackova B: Drug-induced hallucinatory syndrome in a patient with breast cancer after paclitaxel infusion. Support Care Cancer 2012; 20(9):1931～1933.
116.FDALabel(2012-10-26)-SYNRIBO(Omacetaxine Mepesuccinate for Injection)(Teva Pharmaceutical USA, Inc.)
117.O＇Brien S, Kantarjian H, Koller C, et al: Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999a; 93(12):4149～4153.
118.Akbayram S, Dogan M, Akgun C, et al: A desensitization protocol in children with L-asparaginase hypersensitivity. J Pediatr Hematol Oncol 2010; 32(5):e187～e191.
119.FDALabel(2014-04-22)-Oncaspar(Pegaspargase Injection)(Sigma-Tau Pharmaceuticals, Inc.)
120.FDALabel(2015-01-23)-ZYTIGA(Abiraterone Acetate Tablets)(Janssen Biotech, Inc.)
121.Cataliotti L, Buzdar AU, Noguchi S, et al: Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106(10):2095～2103
122.Santen RJ, Worgul TJ, Lipton A, et al: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982; 96:94～101
123.Nubiola-Calonge P, Sancho J, Segura M, et al: Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987; 2:672～674
124.FDALabel(2014-03-11)-EVAMIST(Estradiol Transdermal Spray)(Ther-Rx Corporation)
125.FDALabel(2015-02-27)-CASODEX(Bicalutamide Tablet)(AstraZeneca Pharmaceuticals LP)
126.FDALabel(2015-01-23)-ZYTIGA(Abiraterone Acetate Tablets)(Janssen Biotech, Inc.)
127.Nubiola-Calonge P, Sancho J, Segura M, et al: Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987; 2:672～674.
128.FDALabel(2015-02-26)-FIRMAGON(Degarelix for Injection)(Ferring Pharmaceuticals Inc.)
129.Bardsley V, Cooper P, & Peat DS: Massive lymphocytic infiltration of uterine leiomyomas associated with GnRH agonist treatment. Histopathology 1998; 33:80～82
130.FDALabel(2014-12-22)-SOMATULINE DEPOT(Lanreotide Acetate Injection)(Ipsen Pharma Biotech)
131.Product Information: LUPRON DEPOT-PED 3 month intramuscular injection powder lyophilized for suspension, leuprolide acetate 11.25 mg 30 mg 3 month intramuscular injection powder lyophilized for suspension. Abbott Laboratories (per FDA), North Chicago, IL, 2011.
132.Kauschansky A, Lurie R, & Ingber A: Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment (letter). Acta Derm Venereol (Stockh) 1997; 77(4):333.
133.Product Information: VANTAS(R) subcutaneous implant, histrelin acetate subcutaneous implant. Endo Pharmaceuticals Solutions Inc., Chadds Ford, PA, 2011.
134.FDALabel(2015-02-26)-FIRMAGON(Degarelix for Injection)(Ferring Pharmaceuticals Inc.)
135.FDALabel(2015-10-01)-XTANDI(Enzalutamide Capsules)(Astellas Pharma US, Inc.)
136.Product Information: FASLODEX(R) IM injection, fulvestrant IM injection. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2011.
137.Wiseman LR & McTavish D: Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs 1993; 45:66～84.
138.FDALabel(2015-02-12)-ZOLADEX(Goserelin Acetate Implant)(AstraZeneca Pharmaceuticals LP)
139.Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23(22):5108-5116.
140.Product Information: FARESTON(R) oral tablets, toremifene citrate oral tablets. GTx, Inc, Memphis, TN, 2011.
141.FDALabel(2011-12-23)-FEMARA(Letrozole Tablets)(Novartis Pharmaceuticals Corporation)
142.FDALabel(2014-12-22)-SOMATULINE DEPOT(Lanreotide Acetate Injection)(Ipsen Pharma Biotech)
143.Hsieh YY, Tsai HD, Chang CC, et al: Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. Fertil Steril 2000; 73(4):817～820.
144.Decensi A, Guarneri D, Paoletti MC, et al: Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Eur J Cancer 1991; 27:1100～1104
145.Muller FO, Terblanche J, Schall R, et al: Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 1997; 44:335～341.
146.Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23(22):5108～5116.
147.Product Information: FARESTON(R) oral tablets, toremifene citrate oral tablets. GTx, Inc, Memphis, TN, 2011
148.Barnadas A, Gil M, Gonzalez S, et al: Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 2009; 100(3):442～449.
149.FDALabel(2013-04-02)-SSUPPRELIN LA(Histrelin Acetate Subcutaneous Implant)(Endo Pharmaceuticals Solutions Inc.)
150.FDALabel(2014-09-05)-CAMPATH(Alemtuzumab Injection)(Genzyme Corporation)
151.FDALabel(2015-09-23)-GAZYVA(Obinutuzumab Injection)(Genentech, Inc.)
152.FDALabel(2014-04-17)-ARZERRA(Ofatumumab Injection)(GLAXO GROUP LIMITED)
153.Hayashi H, Okamoto I, & Nakagawa K: Perirenal hematoma associated with bevacizumab treatment. Invest New Drugs 2012; 30(2):808～809.
154.FDALabel(2015-08-17)-ADCETRIS(Brentuximab Vedotin for Injection)(Seattle Genetics, Inc.)
155.FDALabel(2015-03-10)-UNITUXIN(Dinutuximab Injection)(United Therapeutics Corp.)
156.Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25(28):4431-4437.
157.FDALabel(2014-12-03)-BLINCYTO(Blinatumomab for Injection)(Amgen Inc.)
158.FDALabel(2015-04-24)-CYRAMZA(Ramucirumab Injection)(Eli Lilly And Company)
159.Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25(22):3344～3349.
160.FDALabel(2015-10-09)-OPDIVO(Nivolumab Injection)(Bristol-Myers Squibb Company)
161.Hecht J, Posey J, Tchekmedyian S, et al: Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC).. Proc Am Soc Clin Oncol 2006; 2006:237.
162.FDALabel(2015-05-29)-PERJETA(Pertuzumab Injection)(Genentech, Inc.)
163.FDALabel(2015-10-02)-KEYTRUDA(Pembrolizumab for Injection, Injection)(Merck Sharp & Dohme Corp.)
164.FDALabel(2015-04-23)-HERCEPTIN(Trastuzumab Intravenous Infusion)(Genentech, Inc.)
165.FDALabel(2013-10-17)-CIMZIA(Certolizumab Pegol Injection)(UCB, Inc.)
166.FDALabel(2014-04-22)-SYLVANT(Siltuximab for Injection)(Janssen Biotech)
167.Product Information: ZEVALIN(R) intravenous injection, ibritumomab tiuxetan intravenous injection. Spectrum Pharmaceuticals, Inc (per FDA), Irvine, CA, 2011.
168.Hoag JB, Azizi A, Doherty TJ, et al: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009; 28:113.
169.FDALabel(2015-08-17)-YERVOY(Ipilimumab Injection)(Bristol-Myers Squibb Company)
170.FDALabel(2014-08-01)-INLYTA(Axitinib Tablet)(Pfizer Labs)
171.FDALabel(2014-07-23)-ZYDELIG(Idelalisib Tablets)(Gilead Sciences, Inc.)
172.FDALabel(2014-07-24)-ICLUSIG(Ponatinib HydrochlorideTablet)(ARIAD Pharmaceuticals, Inc.)
173.FDALabel(2013-09-30)-BOSULIF(Bosutinib Tablet)(Pfizer Labs)
174.FDALabel(2015-08-12)-SPRYCEL(Dasatinib Tablets)(Bristol-Myers Squibb Company)
175.FDALabel(2014-04-14)-TARCEVA(Erlotinib Tablets)(OSI Pharmaceuticals, LLC)
176.FDALabel(2014-03-31)-CAPRELSA(Vandetanib Tablets)(AstraZeneca Pharmaceuticals LP)
177.Product Information: Iressa(R), gefitinib tablets. AstraZeneca Pharmaceuticals LP, Wilmington, DE, original PI, 2003.
178.FDALabel(2014-12-22)-TYKERB(Lapatinib Ditosylate Tablets)(GlaxoSmithKline)
179.Tougeron D, Wierzbicka-Hainaut E, Osdoit S, et al: Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. Eur J Dermatol 2010; 20(6):854-856
180.Duman BB, Paydas S, Disel U, et al: Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma 2012; 53(9):1706-1708.
181.FDALabel(2012-11-29)-COMETRIQ(Cabozantinib Capsule)(Exelixis, Inc.)
182.FDALabel(2015-09-14)-XALKORI(Crizotinib Capsules)(Pfizer Inc.)
183.FDALabel(2014-12-22)-TYKERB(Lapatinib Ditosylate Tablets)(GlaxoSmithKline)
184.FDALabel(2015-02-13)-LENVIMA(Lenvatinib Mesylate Capsules)(Eisai Inc.)
185.FDALabel(2015-01-27)-TASIGNA(Nilotinib Hydrochloride Capsules)(Novartis Pharmaceuticals Corporation)
186.FDALabel(2015-09-22)-VOTRIENT(Pazopanib Hydrochloride Tablets)(GlaxoSmithKline)
187.Seidel C, Janssen S, Karstens JH, et al: Recall pneumonitis during systemic treatment with sunitinib. Ann Oncol 2010; 21(10):2119～2120.
188.FDALabel(2015-04-13)-STIVARGA(Regorafenib Tablet)(Bayer HealthCare Pharmaceuticals Inc.)
189.FDALabel(2015-07-22)-ZYKADIA(Ceritinib Capsules)(Novartis Pharmaceuticals Corporation)
190.Seidel C, Janssen S, Karstens JH, et al: Recall pneumonitis during systemic treatment with sunitinib. Ann Oncol 2010; 21(10):2119～2120.
191.Shiozawa K, Watanabe M, Takenaka H, et al: Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 2010; 57(101):688～690.
192.FDALabel(2015-07-24)-ODOMZO(Sonidegib Phosphate Capsules)(Novartis Pharmaceuticals Corporation)
193.FDALabel(2015-02-26)-TORISEL(Temsirolimus Injection)(Wyeth Pharmaceuticals Inc.)
194.FDALabel(2015-08-11)-ZELBORAF(Vemurafenib Tablet)(Genentech USA, Inc.)
195.Aasi S, Silkiss R, Tang JY, et al: New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 2013; 149(2):242～243.
196.FDALabel(2014-07-24)-ICLUSIG(Ponatinib HydrochlorideTablet)(ARIAD Pharmaceuticals, Inc.)
197.FDALabel(2013-05-14)-TARCEVA(Erlotinib Tablets)(OSI Pharmaceuticals, LLC)
198.FDALabel(2015-09-22)-VOTRIENT(Pazopanib Hydrochloride Tablets)(GlaxoSmithKline)
199.Duman BB, Paydas S, Disel U, et al: Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma 2012; 53(9):1706～1708.
200.FDALabel(2015-01-29)-IMBRUVICA(Ibrutinib Capsules)(Pharmacyclics, Inc.)
201.Kovarik JM, Sabia HD, Figueiredo J, et al: Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001; 70(5):425～430.
202.FDALabel(2013-07-23)-GILOTRIF(Afatinib Tablets)(Boehringer Ingelheim International GmbH)
203.FDALabel(2014-12-19)-LYNPARZA(Olaparib Capsules)(AstraZeneca Pharmaceuticals LP)
204.FDALabel(2014-01-10)-TAFINLAR(Dabrafenib Mesylate Capsules)(GlaxoSmithKline)
205.FDALabel(2014-12-15)-JAKAFI(Ruxolitinib Phosphate Tablets)(Incyte Corporation)
206.FDALabel(2014-01-08)-MEKINIST(TrametinibDimethylSulfoxideTablets)(GlaxoSmithKlin)
207.FDALabel(2015-09-01)-VARUBI(Rolapitant HCl Tablets)(TESARO, Inc.)
208.Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11(7):1276～1285.
209.Rosen LS, Abdi E, Davis ID, et al: Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24(33):5194～5200.
210.Alexander Drilon, M.D.,Theodore W. Laetsch, M.D.,Shivaani Kummar, M.D.,et al:Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731-739 | | 辞典简介 |
本册工具书共收录846条词条。 |
|